U.K's Heptares Signs Up AstraZeneca In Latest GPCR-Focused Discovery Pact
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca becomes the third Big Pharma in six weeks to sign up for U.K-based Heptares' GPCR stabilizing technology.